All the news Showing 10 of 28 articles from: AASLD 2016Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Models of care Primary care providers can effectively treat people with hepatitis C Liz Highleyman / 07 December 2016 Primary care providers such as non-specialist physicians and nurse practitioners can be quickly trained to provide direct-acting antiviral therapy for hepatitis C with a high level of treatment success and provider satisfaction, according ... Sexual transmission Hepatitis C virus infection is rising among gay and bisexual men in San Diego Liz Highleyman / 30 November 2016 The prevalence of hepatitis C virus (HCV) infection among HIV-positive men who have sex with men in San Diego has increased over the past 15 years, especially among men who do not ... Interferon-free regimens Six weeks of sofosbuvir/ledipasvir cures genotype 1 acute hepatitis C in people without HIV Liz Highleyman / 30 November 2016 A short course of sofosbuvir/ledipasvir (Harvoni) taken for 6 weeks cured 100% of HIV-negative people with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads, according to study results ... Treatment for people living with HIV and HCV Sofosbuvir/ledipasvir is effective for people with HIV/HCV co-infection in real-world clinical practice Liz Highleyman / 28 November 2016 The sofosbuvir/ledipasvir (Harvoni) co-formulation used in real-world clinical practice produced good sustained virological response rates similar to those seen in clinical trials for HIV-positive people with hepatitis C co-infection, according to a pooled ... Antiviral therapy Nucleic acid polymers reduce HBsAg levels and improve control of hepatitis B virus Liz Highleyman / 27 November 2016 The nucleic acid polymers REP 2139 and REP 2165 led to hepatitis B surface antigen (HBsAg) reduction or clearance when combined with tenofovir and pegylated interferon, according to early results from a small ... Adherence to treatment Non-adherence most important risk factor for sofosbuvir/ledipasvir failure Keith Alcorn / 25 November 2016 Research carried out by Mount Sinai Medical Center, New York, found that non-adherence was the strongest risk factor for treatment failure in people taking sofosbuvir/ledipasvir (Harvoni). The main reasons cited for non-adherence ... Cirrhosis Portal hypertension less likely to fall after HCV treatment when liver stiffness is severe Keith Alcorn / 24 November 2016 Curing hepatitis C infection moderately reduces portal hypertension, but has less impact in people with more severe liver stiffness due to fibrosis, Spanish researchers reported at the 2016 AASLD Liver Meeting last week ... Interferon-free regimens Grazoprevir triple regimen demonstrates high cure rates, even for hard-to-treat people Liz Highleyman / 23 November 2016 A new three-drug co-formulation containing Merck's grazoprevir plus the investigational agents MK-3682 and ruzasvir was highly effective for people with hepatitis C virus (HCV) genotypes 1, 2 or 3, with sustained response rates ... Interferon-free regimens 8-week triple DAA combo cures most people with genotype 1-6 hepatitis C Liz Highleyman / 21 November 2016 A three-drug regimen of sofosbuvir, velpatasvir and voxilaprevir taken for 8 weeks demonstrated an overall sustained virological response rate of 95% for previously untreated people with all hepatitis C virus (HCV) genotypes, while ... Screening policy Birth cohort screening and linkage to care for HCV treatment still weak in United States Keith Alcorn / 18 November 2016 Grave weaknesses in hepatitis C screening and linkage to care are still widespread in the United States and threaten to leave a large proportion of baby boomers with hepatitis C ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive